Vacc C5

Drug Profile

Vacc C5

Alternative Names: VACC-C 5

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bionor Pharma
  • Class AIDS vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV infections

Most Recent Events

  • 24 Feb 2014 Pharmacodynamics and adverse events data from a phase I trial in HIV infections released by Bionor Pharma
  • 30 Nov 2013 Bionor Pharma completes a phase I/II trial for HIV infections in Norway (NCT01627678)
  • 27 May 2013 Bionor Pharma completes enrolment in its phase I/II trial for HIV infections in Norway (NCT01627678)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top